## WHAT IS CLAIMED IS:

15

25

- 1. A purified complex comprising endotoxin bound to MD-2.
- 5 2. The complex of claim 1, wherein the endotoxin is a wild-type endotoxin.
  - 3. The complex of claim 1, wherein the endotoxin is a gram-negative bacterial endotoxin.
- 10 4. The complex of claim 3, wherein the gram-negative bacterium is a *Neisseria*, *Escherichia*, *Pseudomonas*, *Haemophilus*, *Salmonella*, or *Francisella* bacterium.
  - 5. The complex of claim 4, wherein the gram-negative bacterium is *Neisseria* meningitidis, Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, Salmonella typhimurium, or Francisella tularensis.
  - 6. The complex of claim 1 having a molecular weight of about 25,000.
- 7. The complex of claim 1, wherein the complex consists essentially of one molecule of endotoxin bound to one molecule of MD-2.
  - 8. The complex of claim 1, wherein the complex is soluble in water.
  - 9. The complex of claim 1, wherein the complex binds to TLR4.

10. The complex of claim 1, wherein the complex produces TLR4-dependent activation of cells.

- 11. The complex of claim 10, wherein the complex produces a half maximal TLR4-dependent activation of cells at a concentration of less than 1 nM of the complex.
- TLR4-dependent activation of cells at a concentration of about 30 pM or less of the complex.
  - 13. The complex of claim 1, wherein the endotoxin is hexa-acylated.

10

- 14. The complex of claim 1, wherein the endotoxin is an under-acylated endotoxin.
- 15. The complex of claim 14, wherein the endotoxin is a tetra-acylated endotoxin.
  - 16. The complex of claim 14, wherein the endotoxin is a penta-acylated endotoxin.
- 20 17. The complex of claim 14, wherein the complex produces less TLR4-dependent activation of cells as compared to a complex comprising an endotoxin that is hexa-acylated.
  - 18. A composition comprising the complex of claim 1.

25

19. The composition of claim 17, further comprising a pharmaceutically acceptable carrier.